The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bristol Myers Squibb’s (NYSE: BMY) Opdivo ...

CM24 plus Opdivo and chemo improved survival in pancreatic cancer with CEACAM1 biomarkers, supporting a biomarker-driven ...

Nivolumab is a monoclonal antibody that works by binding to a protein called PD-1 on a type of immune cell called T-cell.

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the United ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

Jonathan Rockoff is the Health Business editor at The Wall Street Journal, managing a team that reports on pharmaceutical and biotechnology companies, health insurers and hospitals. During the ...

Bristol Myers Squibb & Co (NYSE:BMY) reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 ...

Despite the decrease in total revenues, Bristol Myers Squibb raised its 2025 revenue guidance to a range of approximately $45 ...

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

Despite a dip in sales and a recent schizophrenia stumble, the company drew an optimistic outlook for sales for the rest of ...

The pharmaceutical company on Thursday said it raised its full-year guidance for revenue in the year to a range of $45.8 billion to $46.8 billion, up from a previous forecast of $45.5 billion.